Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (2)
P 2 (1)

Trial Status

Recruiting2
Withdrawn1

Clinical Trials (3)

Showing 3 of 3 trials
NCT04991870Phase 1Recruiting

Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM

NCT05052957Phase 2Recruiting

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

NCT04854044Phase 1Withdrawn

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Showing all 3 trials

Research Network

Activity Timeline